Sultanate of Oman Ministry of Health Drug Safety Center Muscat



سلطنة عُمان وزارة الصحة مركز سلامة الدواء مسقط

To:

THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES

Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)

Director General of Engineering Affairs, MOH

Director General of Royal Hospital

Director General of Khoula Hospital

Director General of Medical Supplies (MOH)

Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)

Hospital Director (Al Nahda Hospital)

Hospital Director (Al Massara Hospital)

The Head of Medical Services in SQU Hospital

The Head of Medical Services in Royal Oman Police

The Head of Medical Services in Ministry of Defence

The Head of Medical Services in The Diwan

The Head of Medical Services in The Sultan's Special Force

The Head of Medical Services in Internal Security Services

The Head of Medical Services in Petroleum Development of Oman

The Head of Medical Services in LNG Oman

ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No 91 dated 27/6/2024 Regarding NCMDR Field Safety Notice of DEFIGARD HD-7 from (mfr: Schiller AG).

Copy to:

- · Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DSC
- Director of Pharmacovigilance & Drug Information Dept, DSC
- Director of Drug Control Department, DSC
- · Director of Pharmaceutical Licensing Department, DSC
- Director of Central Quality Control Lab., DSC
- Supdt. of Central Drug Information





Sultanate of Oman Ministry of Health Drug Safety Center Muscat



سلطنة عُمـان وزارة الصحـة مركز سلامة الـدواء مسقط

Circular No. 9 / / 2024

20 -12-1445 H 27-06-2024



Field Safety Notice of DEFIGARD HD-7 from Schiller AG.

| Source | NCMDR - National Center Medical Device Reporting- SFDA. https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=4&rid=21076 |
|-----------------------|---|
| Product | DEFIGARD HD-7. |
| Description | Medical electronics / Electromedical devices – electrotherapy. |
| Manufacturer | Schiller AG. |
| Local agent | Waleed Pharmacy & Stores LLC. |
| The affected products | All DEFIGARD HD-7 devices. |
| Reason | Correction of software faults: 1) An automatic self-test time stamp fault (on 01/01/1970) can set off an alarm on the device without there being a technical fault. 2) In rare cases, there are reports that when the device is switched on for manual defibrillation, the defibrillator was in synchronized defibrillation mode instead of in direct mode. |
| Action | Customers/users are to follow the instructions provided by Schiller Medical in the attachment. Schiller Medical is releasing a new software version that corrects these faults. Contact the local agent for remedial action. |
| comments | Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical device to Department of Medical Device Control through the E-mail: Med-device@moh.gov.om |

Dr. Mohammed Hamdan Al Rubaie Director General







SCHILLER MEDICAL 4, rue Louis Pasteur 67160 Wissembourg – France

Customer assistance:



Safety notice reference: IM0499

May 2024

Safety notice DEFIGARD HD-7 monitor and defibrillator

| DEI IGAILD IID | i illollitoi alla aciibilliatoi |
|---|---------------------------------|
| For the attention of users of DEFIGARD HD-7 | monitors and defibrillators |
| Local contact | |

| 3. Main clinical use of device | 1. Device information | | | | |
|--|-----------------------|---|--|--|--|
| Trade names DEFIGARD HD-7 3. Main clinical use of device Monitoring and automated external defibrillation | 1. | Туре | | | |
| DEFIGARD HD-7 3. Main clinical use of device Monitoring and automated external defibrillation | DEFIGA | ARD HD-7 | | | |
| Monitoring and automated external defibrillation | 2. | Trade names | | | |
| Monitoring and automated external defibrillation | DEFIGA | ARD HD-7 | | | |
| | 3. | Main clinical use of device | | | |
| 4. Models concerned by the notice | Monito | oring and automated external defibrillation | | | |
| M. IVICUTED CONCENTRAL INC. IV THE HUNCH | 1 | Models concerned by the notice | | | |
| All DEFIGARD HD-7 devices | 27000 | | | | |

2 Reason for safety notice

1. Description of problem

Correction of software faults: 1) An automatic self-test time stamp fault (on 01/01/1970) can set off an alarm on the device without there being a technical fault. 2) In rare cases, there are reports that when the device is switched on for manual defibrillation, the defibrillator was in synchronised defibrillation mode instead of in direct mode.

Risk

Could lead to delayed patient treatment.

3. Source of the problem

The faults are software-related.



3. Action to mitigate the risk

Immediate steps

Until your DEFIGARD HD-7 is updated with the software version 02:

1) If there is a self-test alarm, please verify the dates of the latest self-tests. If you find a self-test dated 01/01/1970, the device memory must be reformatted, after first saving your data. The procedure is described in sections 8.1 Post-intervention and 9.1.1 Device settings menu.

2) After switching on in manual defibrillation mode, check that the defibrillator is in the defibrillation mode appropriate for the procedure to be applied. Change modes if needed.

Corrective action

Schiller Medical is releasing a new software version that corrects these faults.

With this Soft02 version and above, the time stamping of self-tests is made more reliable, and the manual defibrillator always starts in direct defibrillation mode.

Please update your DEFIGARD HD-7 as soon as possible, using the procedure described in paragraph 10.3 of the manual

Additional information: The software also includes another modification: the default energy for internal defibrillation (using defibrillation paddles) has been reduced to 10 Joules. It remains user-modifiable.

Please attach a copy of this safety notice to the instructions for use, and insert one copy in each DEFIGARD HD-7 bag to inform its users.

| | cob | y in each Derigand no-7 dag to | inform its users. | | | | |
|----|-----|--|------------------------|--------------------------------|--|--|--|
| 1. | | ponse required from the user ase see the modalities in the letter fr | om your distributor | YES | | | |
| | | 4. General information | | | | | |
| 4. | 1. | Type of notice | Initial | | | | |
| | | 2. additional information expected while monitoring the FSN? | None | | | | |
| | 2. | The competent (regulatory) author to customers. | ity of your country ha | s been informed of this notice | | | |
| | 3. | Surname/signature | Quality and Regulator | ry Affairs Director | | | |

| Circulation of this safety notice |
|---|
| This notice is to be passed on to all those who need to be informed within your organisation or |
| any other organisation to which devices that are potentially concerned have been transferred. |

